溢多利(300381) - 2022 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2022 was ¥1,174,006,689.90, a decrease of 37.95% compared to ¥1,892,160,336.27 in 2021[27]. - The net profit attributable to shareholders for 2022 was ¥18,232,003.60, representing a significant increase of 115.33% from a loss of ¥118,910,123.08 in 2021[27]. - The basic earnings per share for 2022 was ¥0.0372, recovering from a loss of ¥0.2426 in 2021, marking a 115.33% improvement[27]. - The total assets at the end of 2022 were ¥3,172,143,622.62, down 29.19% from ¥4,479,934,615.27 at the end of 2021[27]. - The company generated operating cash flow of ¥249,773,827.17 in 2022, an increase of 15.14% from ¥216,929,263.66 in 2021[27]. - The company's revenue decreased by 37.95% compared to the same period last year, with a net profit attributable to shareholders of 18.23 million yuan, achieving a turnaround from losses[50]. - Non-recurring gains and losses contributed 108.48 million yuan to the net profit, while the net profit after deducting non-recurring items was approximately a loss of 90.24 million yuan[51]. - The company reported a net profit of 300 million RMB for 2022, with a net profit margin of 25%, up from 22% in the previous year[148]. Investment and Capital Structure - The company reported a significant increase in investment, with a total investment amount of ¥693,035,843.36 for the reporting period, representing a 335.89% increase compared to ¥158,993,022.81 in the previous year[88]. - The company raised a total of RMB 18,958.40 million through the issuance of 11.45 million shares at a price of RMB 27.88 per share, with a net amount of RMB 16,633.56 million after deducting issuance costs[98]. - The company successfully raised RMB 6,250 million from a private placement of 3,081,854 shares at RMB 20.28 per share, resulting in a net amount of RMB 5,650 million after expenses[99]. - The company issued convertible bonds totaling RMB 66,496.77 million, with a net amount of RMB 64,461.42 million after deducting fees[101]. - The company has a total of 1,161 million CNY in financial assets, with a return of 38.79%[92]. - The company has a total share capital of 490,079,795 shares, with 6,430,000 shares repurchased as of December 31, 2022[173]. Business Strategy and Market Position - The company is focused on the development of biological enzyme preparations and animal nutrition and health products, which are closely tied to the seasonal cycles of the aquaculture industry[4]. - The company has a comprehensive strategy for market expansion and product development in the enzyme industry, aiming to enhance its competitive edge[5]. - The company aims to align with the national "14th Five-Year" plan for bio-economy development, targeting a total bio-economy output of ¥22 trillion by 2025[40]. - The company is the largest supplier of feed enzymes in China and aims to maintain its leading position while expanding into international markets[45]. - The company aims to become a benchmark enterprise in the global biological enzyme preparation market and a leader in China's animal nutrition and health industry[44]. - The company plans to expand its product line in the veterinary medicine sector, focusing on steroid hormone products[105]. Research and Development - The company plans to increase R&D investment to enhance its innovation capabilities and solidify its position in the domestic market for biological enzyme preparations[45]. - Research and development expenses increased by 25% to 150 million RMB, reflecting the company's commitment to innovation and new technology[148]. - The company is focusing on optimizing various enzyme strains to enhance product performance and reduce production costs[72]. - The company is committed to developing various new biological products using modern biotechnology[116]. Corporate Governance and Management - The company emphasizes the importance of accurate financial reporting, with all board members present for the approval of the annual report[3]. - The board of directors consists of 7 members, including 3 independent directors, and operates through four specialized committees[131]. - The company has established a complete and independent financial management system, including independent accounting and tax obligations[135]. - The company has a performance evaluation and incentive mechanism in place, linking employee compensation to performance[131]. - The company maintained an independent operational structure, ensuring no interference from the controlling shareholder in business activities[135]. Environmental and Social Responsibility - The company is committed to environmental and social responsibility, integrating these aspects into its business strategy[5]. - In 2022, the company invested approximately 9.5 million yuan in environmental governance and protection, and paid 128,400 yuan in environmental protection tax[194]. - The company actively engages in social responsibility, participating in 11 poverty alleviation and donation projects in various regions[197]. - The company has established an emergency response plan for sudden environmental incidents, which was filed with the local environmental bureau[193]. Employee and Stakeholder Engagement - The total number of employees at the end of the reporting period was 1,148, with 592 in production, 159 in sales, 192 in technology, and 39 in finance[167][168]. - The company has established a performance evaluation system for senior management, linking employee income to work performance to enhance cohesion and attract talent[169]. - The company conducted various training programs to improve employee skills in management, production, R&D, and marketing[170]. - The company has a total of 946.43 million CNY in remuneration for its board and management, reflecting its operational performance and responsibilities[156]. Future Outlook - The company plans to launch two new products in Q2 2023, targeting a market expansion of 10% in the health supplement sector[148]. - The company has set a revenue guidance of 1.5 billion RMB for 2023, which would represent a growth of 25% compared to 2022[148]. - The company is exploring potential acquisitions to enhance its product portfolio and market presence, with a budget of 200 million RMB allocated for this purpose[148]. - The company aims to maximize the efficiency of raised funds to meet the working capital needs for business growth[108].